EU approves Avastin for lung cancer

Aug 24, 2007

The European Union has approved the anti-cancer drug Avastin as a first-line treatment for advanced lung cancer.

European officials said the drug, which is already approved in the United States, can be used as a first-line treatment for patients with advanced non-small cell lung cancer in combination with platinum-based chemotherapy.

Swiss drug maker Roche said Avastin is the only first-line therapy to demonstrate improved survival benefits beyond one year in patients with advanced lung cancer, the company said Friday in a release.

Roche said Avastin is the first treatment that inhibits angiogenesis, which is the growth of a network of blood vessels that supply nutrients and oxygen to cancerous tissues.

Avastin targets a naturally occurring protein called VEGF (Vascular Endothelial Growth Factor), a key mediator of angiogenesis, thus choking off the blood supply that is essential for the growth of the tumor and its spread throughout the body

The drug is also used in the treatment of breast, colorectal and kidney cancers.

Copyright 2007 by United Press International

Explore further: FDA approves AbbVie combo hepatitis C treatment

add to favorites email to friend print save as pdf

Related Stories

Fun cryptography app pleases students and teachers

6 hours ago

Up on Google Play this week is Cryptoy...something that you might want to check out if you or someone you know wishes entry into the world of cryptography via an educational and fun app. You learn more about ciphers and keys; you ...

Recommended for you

Xtoro approved for swimmer's ear

23 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

23 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.